Just as John Hopkins University (JHU) found the first-of-its-kind biomarker signature for melanoma to predict immunotherapy response using biomarkers in Akoya’s MOTiF™ Panel kit, with this award we can help you discover your own Spatial Phenotypic Signature (SPS).
Recent studies have established multiplex immunofluorescence (mIF) as an invaluable tool for clinical and translational tumor tissue immune profiling. Akoya has developed the concept of spatial phenotyping – the study of the tumor microenvironment, with cutting-edge multiplexed imaging technologies, at single cell resolution, for true spatial analysis and phenotypic signature discovery. Developed for speed and simplicity, our panel designs provide a validated end-to-end solution for unparalleled quantitative data for translational immuno-oncology research and contain 6 of the most clinically relevant markers.
|PD-1/PD-L1 Axis Carcinoma||CD8, CD68, FoxP3, PD-1, PD-L1, PanCK|
|PD-1/PD-L1 Axis Melanoma||CD8, CD68, FoxP3, PD-1, PD-L1, Sox10/S100|
|Tumor Infiltrating Lymphocyte||CD4, CD8, CD20, FOXP3, CD45RO, PanCK|
|Solid Tumor Immunology||CD4, CD8, CD20, CD68, FoxP3, PanCK|
|Tumor Infiltrating Lymphocyte (macrophages)||CD4, CD8, CD20, CD68/CD163, FoxP3, PanCK|
|Tumor Infiltrating Lymphocyte (B cells)||CD4, CD8, CD20, CD3, FoxP3, PanCK|
|Tumor Infiltrating Lymphocyte (TAM)||CD4, CD8, FoxP3, CD68, CD163, PanCK|
|John Hopkins University Melanoma||PD-1, PD-L1, CD8, CD163, FOXP3, SOX10|
Discover Your Spatial Phenotypic Signature with our panel designs or design your own
Award: For the recipient of this award, Akoya will design and validate an immuno-oncology (IO) panel, consisting of your six preferred markers, and stain and image up to 50 FFPE whole-slide tissue samples to provide data to help prove your SPS hypothesis on your precious clinical samples.
How to Apply: Complete the application form and tell us the markers you wish to include in your ideal 6-plex IO panel. You can choose from our list of markers or specify your own markers to create a custom 6-plex panel. Add a short abstract (less than 300 words) describing the biological or clinical significance of your panel, e.g., towards the interrogation of the tumor microenvironment and / or its immunotherapeutic predictive value as correlated to patient outcomes.
Terms: Applications will close on Friday September 17, 2021. This award is subject to the Spatial Phenotypic Signature Award Terms and Conditions which contain eligibility restrictions. No purchase is necessary to enter; void where prohibited.